Dar Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women's health products in the United States. The company is headquartered in San Diego, California.
| Revenue (TTM) | $1.37M |
| Gross Profit (TTM) | $3.33M |
| EBITDA | $-8.98M |
| Operating Margin | -1583.00% |
| Return on Equity | -2543.00% |
| Return on Assets | -39.30% |
| Revenue/Share (TTM) | $0.10 |
| Book Value | $-0.04 |
| Price-to-Book | 29.40 |
| Price-to-Sales (TTM) | 10.23 |
| EV/Revenue | 1.608 |
| EV/EBITDA | -2.06 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 499.60% |
| Shares Outstanding | $19.38M |
| Float | $12.95M |
| % Insiders | 12.34% |
| % Institutions | 13.66% |
Volatility is currently contracting
New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million
Video webcast now available here
Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript
Daré's proprietary formulation of topical sildenafil cream, 3.6% was well tolerated across all evaluated doses in the clinical study, with minimal systemic exposure Company continues activities necessary to advance its Sildenafil Cream toward the FDA's 505(b)(2) regulatory pathway* while in parallel launching DARE to PLAY™ Sildenafil Cream, the 503B compounded version of its proprietary sildenafil cream formulation**
President & CEO, Sabrina Martucci Johnson, discusses the Company's shift to commercial stage, upcoming revenue opportunities, Ovaprene's positive interim Phase 3 results and what could drive value over the next 12–18 months Access the segment here
National recognition comes as Daré Bioscience advances a multi-product women's health strategy across commercialization, clinical development and first-in-category innovation National recognition comes as Daré Bioscience advances a multi-product women's health strategy across commercialization, clinical development and first-in-category innovation
SAN DIEGO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (Nasdaq: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it has entered into a definitive securities purchase agreement with institutional investors for the purchase and sale of 4,379,581 shares of the Company's common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof), at a price of $1.37 per share of common stock (or $1.3699 per pre-funded warrant) in a registered direct offering priced at-the-market under Nasdaq rules. Each pre-funded warrant will be exercisable upon issuance at an exercise price of $0.0001 per share and will expire when exercised in full.
Daré Bioscience, Inc. (DARE) Q2 2026 Earnings Call Transcript
Company launches Flora Sync LF5™, the company's first directly commercialized product, began generating revenue in July
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it will host a corporate update conference call and webcast at 4:30 PM Eastern Time on Thursday, August 13, 2026, to review its financial results for the quarter ended June 30, 2026 and to provide a company update.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DARE and any ticker you trade — then tracks every position and per-strategy win rate.
